Pharmaceutical Benefits Scheme (PBS) Listings 1 November 2026

Please find below information relating to new and amended Pharmaceutical Benefits Scheme (PBS) listings implemented on **1 November 2026**.

This information relates to the administration of these listings by Services Australia. For further information on broader PBS changes, please visit the PBS website. Relevant information and authority application forms have been updated and can be accessed through the Services Australia website.

Moderate to severe ulcerative colitis; severe active juvenile idiopathic arthritis; severe chronic plaque psoriasis; severe Crohn's disease; complex refractory fistulising Crohn's disease; severe psoriatic arthritis; vision threatening non-infectious uveitis; enthesitis/spondylitis related juvenile idiopathic arthritis; severe active rheumatoid arthritis; ankylosing spondylitis and moderate to severe hidradenitis suppurativa

Adalimumab (20 mg/0.2 mL injection, 0.2 mL syringe; 40 mg/0.4 mL injection, 2 x 0.4 mL pen devices; 80 mg/0.8 mL injection, 0.8 mL pen device) (Amgevita®) is a new biosimilar brand now listed on the PBS for the treatment of moderate to severe ulcerative colitis, severe active juvenile idiopathic arthritis, severe chronic plaque psoriasis, severe Crohn's disease, complex refractory fistulising Crohn's disease, severe psoriatic arthritis, vision threatening non-infectious uveitis, enthesitis/spondylitis related juvenile idiopathic arthritis, severe active rheumatoid arthritis, ankylosing spondylitis and moderate to severe hidradenitis suppurativa.

Cystic fibrosis

ELEXACAFTOR + TEZACAFTOR + IVACAFTOR (&) IVACAFTOR (elexacaftor 100 mg + tezacaftor 50 mg + ivacaftor 75 mg granules [28] (&) ivacaftor 75 mg granules [28], 56) (Trikafta®) has had an update to restrictions to allow patients aged 6-11 years weighing less than 30 kg to use either the granule or tablet formulation of the same dose for the treatment of cystic fibrosis. Authority applications for initial and continuing treatments can be made using the Online PBS Authorities system or in writing.

Spinal muscular atrophy (SMA)

Onasemnogene abeparvovec (20 trillion vector genomes/mL injection; solution for injection, customised based on patient weight) (Zolgensma®) has had an update to its restrictions for the treatment of SMA to include paediatric patients weighing up to 21 kg. Authority applications for treatment can be made using the Online PBS Authorities system or in writing.

Advanced Stage CD30 positive Hodgkin lymphoma

Brentuximab vedotin (50 mg injection, 1 vial) (Adcetris®) has had an update to the restrictions for the treatment of Advanced Stage CD30 positive Hodgkin lymphoma. Applications for treatment can be made using the Online PBS Authorities system or by telephone.

Active moderate to severe thyroid eye disease

Teprotumumab (500 mg injection, 1 vial) (Tepezza®) is now listed on the PBS for the treatment of active moderate to severe thyroid eye disease. Authority applications for initial treatment can be made using the Online PBS Authorities system or by telephone. Applications for continuing treatment are Authority required (STREAMLINED).

Uncontrolled chronic obstructive pulmonary disease (COPD)

Mepolizumab (100 mg/mL injection, 1 mL pen device) (Nucala®) for the treatment of uncontrolled COPD has had an update to its restrictions to clarify assessment of adequate response for continuing treatment.

Moderate to severe spasticity of the lower limb in adults following an acute event

IncobotulinumtoxinA (100 units injection, 1 vial) (Xeomin®) is now listed on the PBS for the treatment of moderate to severe spasticity of the lower limb in adults following an acute event. Authority applications for treatment are Authority required (STREAMLINED).

Diabetes mellitus type 2

Acarbose (50 mg tablet, 90; 100 mg tablet, 90) ((Morningside Healthcare, UK)®) is now listed on the PBS for the current supply shortage under Section 19A. It is listed as an Unrestricted and a Restricted benefit.

Hydatid disease

Albendazole (400 mg tablet, 60) (Albendazole (Micro Labs, Germany)®) is now listed on the PBS for the current supply shortage under Section 19A. Applications for treatment are Authority required (STREAMLINED).

Asthma

Salbutamol (2.5 mg/2.5 mL inhalation solution, 20 x 2.5 mL ampoules) (PMS-SALBUTAMOL (Canada)®) is now listed on the PBS for the current supply shortage under Section 19A. It is listed as a Restricted benefit.

Malignant lymphomas; Neuroblastoma

Cyclophosphamide (1 g injection, 1 vial; 2 g injection, 1 vial) (Cyclophosphamide (Seacross Pharmaceuticals, UK)®) is now listed on the PBS for the current supply shortage under Section 19A. It is not “a”-flagged to existing listings.

Additions to PBS listings for 60-day prescriptions

The following medicine is now available for 60-day prescriptions on the PBS:

Familial heterozygous hypercholesterolaemia; non-familial hypercholesterolaemia; familial homozygous hypercholesterolaemia

Evolocumab (140 mg/mL injection, 1 mL pen device) (Repatha®) is now available for 60-day prescriptions on the PBS for the treatment of familial heterozygous hypercholesterolaemia, non-familial hypercholesterolaemia and familial homozygous hypercholesterolaemia. Applications for continuing treatment are Authority required (STREAMLINED).

1 November 2026 delisted PBS listings

Primary biliary cholangitis (previously known as Primary biliary cirrhosis)

Elafibranor (80 mg tablet, 30) (Iqirvo®) for the treatment of primary biliary cholangitis (previously known as primary biliary cirrhosis) no longer has a listing for Grandfather arrangements.

Paroxysmal nocturnal haemoglobinuria (PNH)

Iptacopan (200 mg capsule, 56) (Fabhalta®) for the treatment of PNH no longer has a listing for Grandfather arrangements.

Multiple sclerosis

Glatiramer acetate (40 mg/mL injection, 12 x 1 mL pen devices) (Copaxone®) for the treatment of multiple sclerosis has been de-listed.

Osteoarthritis; Rheumatoid Arthritis

Meloxicam (15 mg capsule, 30) (Mobic®) for the treatment of osteoarthritis and rheumatoid arthritis has been de-listed.

IMPORTANT INFORMATION

Integrated clinical and prescribing software

Several clinical and prescribing software developers now have products available for use to request PBS authority approval directly from your clinical and prescribing software. This means you can request PBS authority approval as part of generating the authority prescription rather than calling, applying in writing or self-serving through the PBS Authorities tile in HPOS. For more information, speak with your software provider. A list of integrated software products can be found on our website by searching QC71058.

PBS Authorities items criteria

Under the PBS, medicines are made available based on recommendations from the Pharmaceutical Benefits Advisory Committee (PBAC). Patients must meet the set criteria to be eligible for PBS subsidised medicines. Services Australia are unable to provide approval for an Authority Required medication where a patient does not meet the criteria established by PBAC.

If you have concerns or questions about the eligibility criteria set by the PBAC, you can contact the Department of Health, Disability and Ageing by email at pbs@health.gov.au.

REMINDERS

PBS Authorities – written authority application forms

To align with PBS listing changes, forms are updated on the first of the month. Using the most recent form will help avoid delays in obtaining authority approval. Search the Services Australia website to access the most recent forms.

Correct PBS item code

When requesting PBS authorities via the Online PBS Authorities system, ensure you have selected the correct medicine to match what is on the prescription. This will avoid delays with providing patients with the medication they require.

Ensuring you are providing accurate data

It's important to ensure you are providing accurate and up to date information when completing an authority application. Failure to do so may result in your authority request being rejected.

For more information about the Online PBS Authorities system visit www.servicesaustralia.gov.au/hppbsauthorities

Services Australia has a broad range of educational resources on the Health Professional Education Resources website. This includes simulations, podcast and an infographic on the Online PBS Authorities system. Visit https://hpe.servicesaustralia.gov.au/pharmaceutical-benefits-scheme.html

Visit servicesaustralia.gov.au/hpwrittenauthoritydrugs on the Services Australia website to find the most up to date authority application form for each drug, program or condition.